300108 Ji Yao Holding Group
- 1.60
- -0.06-3.61%
Ji Yao Holding Group News
*ST Jiyao (300108.SZ): Received a court decision to extend the pre-restructuring period
Gelonghui on May 27丨*ST Jiyao (300108.SZ) announced that the company received the “Decision” delivered by Tonghua Intermediate Court. The main contents are as follows: On May 22, 2024, the temporary manager of Ji Yao Holding Group Co., Ltd. and the company applied to Tonghua Intermediate Court to extend the pre-restructuring period of Ji Yao Holdings. The Tonghua Intermediate Court believes that the application of the temporary manager and company of Ji Yao Holding Group Co., Ltd. complied with the relevant regulations and decided to extend the pre-restructuring period of Ji Yao Holdings by three months until August 27, 2024.
ST Pharmaceutical (300108.SZ): The company's stock trading was subject to delisting risk warning, stock trading suspended
Gelonghui announced on April 28 | ST Jiyao (300108.SZ). After an audit, the company's net assets at the end of the 2023 period were negative. It touches upon the provisions of section 10.3.1 (2) of the “Shenzhen Stock Exchange GEM Stock Listing Rules”: “The net assets at the end of the audited fiscal year were negative, or the net assets at the end of the most recent fiscal year were negative after retroactive restatement”. The company's 2023 audit agency Central Certified Public Accountants (Special General Partnership) issued an audit report where it was unable to express an opinion on the company's 2023 financial statements, touching on “Shenzhen
ST Pharmaceutical (300108.SZ): Net loss of 40.85 million yuan in the first quarter
Gelonghui, April 28 | ST Jiyao (300108.SZ) released its first quarter report. Operating income was 75.46 million yuan, up 5.36% year on year, net loss of 40.85 million yuan, net loss of 37.94 million yuan, basic earnings per share -0.0613 yuan.
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
Sihuan Pharmaceutical Holdings (HKG:0460) unit Longyu Hongda Investment Management formed a consortium with other parties for the restructuring of Ji Yao Holding (SHE:300108) following its bankruptcy
ST Jiyao (300108.SZ): Received a decision to initiate pre-restructuring and appoint a temporary manager
Gelonghui November 27丨ST Jiyao (300108.SZ) announced that through a decision of the Tonghua Intermediate Court, pre-restructuring procedures were initiated for the company during the bankruptcy and restructuring preparation stage, and the bankruptcy and restructuring and liquidation team of Jiyao Holding Group Co., Ltd., which was founded by the Meihekou Municipal People's Government, was appointed as the interim manager.
[BT Financial Report Instantaneous Analysis] ST Jiyao's 2023 Quarterly Report: Operating income and profit declined, net cash flow declined sharply
This financial report was announced on 2023-10-25 18:30:26 ST Jiyao (stock code: 300108) is an enterprise group centered on the pharmaceutical and health industry. Its main business includes the pharmaceutical industry, pharmaceutical business, pharmaceutical research and development, medical care, and pharmaceutical industry investment. Its pharmaceutical industry mainly produces Chinese and Western proprietary medicines, biopharmaceuticals, and health food products, covering a variety of dosage forms. The company has about 170 pharmaceutical production codes, including national medical insurance products, medical insurance catalogue products, and national exclusive varieties or dosage forms. In addition, the company also has new drug projects under development. From assets
ST Jiyao (300108.SZ) released results for the first three quarters, with a net loss of 144 million yuan
ST Jiyao (300108.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 2...
*ST Jiyao (300108.SZ) stock abbreviation will be changed to “ST Jiyao” and trading will be suspended for 1 day from the opening of the market on October 24
*ST Jiyao (300108.SZ) announced that the company's stock will be on October 24, 2023 (week...
*ST Jiyao (300108.SZ) released results for the first half of the year, with a net loss of 91.89 million yuan, narrowing by 62.44%
*ST Jiyao (300108.SZ) released the 2023 semi-annual report. The company's revenue was 1.59...
*ST Jiyao (300108.SZ): To apply to the court for bankruptcy and restructuring matters
On June 30, 丨*ST Jiyao (300108.SZ) announced that it intends to apply to the People's Court for bankruptcy and restructuring of the company and to initiate pre-restructuring proceedings on the grounds that the company is unable to pay maturing debts on time and clearly lacks solvency, but has bankruptcy and restructuring value. The matter still needs to be reviewed by the shareholders' meeting.
Chinese Securities Regulator Slaps Ji Yao Holding With 2 Million Yuan Fine Over Disclosure Breaches
03:34 AM EST, 12/27/2022 (MT Newswires) -- The China Securities Regulatory Commission imposed a 2 million yuan fine on Ji Yao Holding Group (SHE:300108) for failure to disclose major litigation matter
The traditional Chinese medicine sector opened lower, and 002907.CN Pharmaceuticals (Huasen) fell 8.39%.
[Caihua Social News] in early trading today, as of 09:30, the traditional Chinese medicine plate opened low. 002907.CN fell 8.39% to 18.01 yuan, 300108.CN fell 4.50% to 4.88 yuan, 600479.CN fell 4.42% to 13.42 yuan, 300147.CN fell 3.95% to 8.03 yuan, 002603.CN fell 3.76% to 24.09 yuan, Hongri Pharmaceutical (300026.CN) fell 3.60% to 8.31 yuan, Chinese new medicine
News flash: Chinese medicine stocks led the decline at the start of the day. Watson Pharmaceuticals once hit the limit.
January 13 news, Chinese medicine stocks led the decline, as of press time, Huasen Pharmaceutical once hit the limit, auspicious Pharmaceutical Holdings, Yiling Pharmaceutical, Shensheng Pharmaceutical, Xintian Pharmaceutical, Qianjin Pharmaceutical and so on fell.
News flash: the traditional Chinese medicine sector rebounded in the afternoon and many stocks such as Hansen Pharmaceutical rose by the daily limit.
January 12 news, the traditional Chinese medicine plate rebounded in the afternoon, as of press time, Hansen Pharmaceutical, Long John Pharmaceutical before the limit, auspicious Pharmaceutical Holdings, Watson Pharmaceutical rose. On the news side, China Galaxy Securities Research News said: national policy continues to support the development of traditional Chinese medicine industry. Traditional Chinese medicine industry is one of the national key protection industries, the relevant national policies actively encourage the development of traditional Chinese medicine industry and traditional Chinese medicine prepared slices industry, the relevant regulatory departments of various provinces also formulate relevant policy provisions to increase support to the traditional Chinese medicine industry and related enterprises. The continuous improvement of the industry regulatory system and the support of industry regulations and policies are conducive to the sustained and healthy development of the traditional Chin
On January 11, the main forces of the two cities reduced their holdings of the first 50 stocks.
When A shares closed on January 11, the Prev index fell-0.73% to close at 3567.44 points; the Shenzhen Composite Index fell-1.27% to close at 14223.35 points; and the gem index fell-1.28% to close at 3056.15 points. Prev fluctuated downward in the afternoon, the Shenzhen Composite Index and gem index fell by more than 1.3%, the Kechuang 50 index fell nearly 2%, and the early strong sectors such as metasmology, virtual digital human, digital currency and so on were obviously pulled back. Pharmaceutical and COVID-19 testing stocks rose against the market, while Tianrui Instruments, Yafuilong, Anxu Biology and Komei Diagnostics 20CM rose by the daily limit, Jiu'an Medical Care, auspicious Pharmaceutical Holdings, Huasen Pharmaceutical, Dongdong.
On January 11, the main forces of the two cities increased their holdings of the top 50 stocks.
When A shares closed on January 11, the Prev index fell-0.73% to close at 3567.44 points; the Shenzhen Composite Index fell-1.27% to close at 14223.35 points; and the gem index fell-1.28% to close at 3056.15 points. Prev fluctuated downward in the afternoon, the Shenzhen Composite Index and gem index fell by more than 1.3%, the Kechuang 50 index fell nearly 2%, and the early strong sectors such as metasmology, virtual digital human, digital currency and so on were obviously pulled back. Pharmaceutical and COVID-19 testing stocks rose against the market, while Tianrui Instruments, Yafuilong, Anxu Biology and Komei Diagnostics 20CM rose by the daily limit, Jiu'an Medical Care, auspicious Pharmaceutical Holdings, Huasen Pharmaceutical, Dongdong.
Analysis of the daily limit of Jilin Pharmaceutical Holdings on January 11: traditional Chinese medicine, pharmaceutical business, pharmaceutical concept hot stocks
Lucky Pharmaceutical Holdings rose the limit to close, closing price 4.7 yuan. The stock rose by the daily limit at 09:53, but did not open the limit. The closing capital was 75.7212 million yuan, accounting for 3.63% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 84.2668 million yuan, the net inflow of hot capital was 67.6055 million yuan, and the net outflow of retail funds was 43.9375 million yuan. The capital flow in the past five days is shown in the following table: the stock is a hot stock of traditional Chinese medicine, pharmaceutical business and pharmaceutical concept. On the same day, the concept of traditional Chinese medicine rose 2.73%, the concept of pharmaceutical business rose 2.38%, and the concept of medicine rose 1.79%. This article
[dynamic stocks] the traditional Chinese medicine sector pulled up, and Jilin Pharmaceutical Holdings (300108.CN) rose 19.9%.
[Caihua Social News] in early trading today, as of 10:00, the traditional Chinese medicine plate pulled up. Lucky Pharmaceutical Holdings (300108.CN) rose 19.90 percent to 4.7 yuan, Longshen Rongfa (300534.CN) rose 11.52 percent to 14.91 yuan, Kunming Pharmaceutical Group (600422.CN) rose 10.00 percent to 12.65 yuan, 002317.CN (002317.CN) rose 10.00 percent to 13.75 yuan, 603963.CN (Dali) rose 9.98 percent to 9.37 yuan, and Dong E E Jiao (000423.CN) rose 8.84 percent to 49.02 yuan.
Two controlling shareholders are involved in an equity dispute. Jilin Pharmaceutical Holdings receives a letter of concern from Shenzhen Stock Exchange.
On January 5, the Shenzhen Stock Exchange issued a letter of concern to Jilin Pharmaceutical Holdings, requesting to explain the details of the equity transfer dispute between the current controlling shareholder, Materia Medica and the former controlling shareholder, Lu Zhongkui. The concern letter pointed out that on the evening of December 31, 2021, Jilin Pharmaceutical Holdings disclosed that 2.61% of the shares held by the company's controlling shareholder, Bencaohui Pharmaceutical, had been judicially frozen because of a dispute over equity transfer between Bencaohui Pharmaceutical and Lu Zhongkui, the company's shareholder. The shares held by Bencaohui Pharmaceutical were applied for property preservation by Lu Zhongkui. In this regard, the Shenzhen Stock Exchange asked Jilin Pharmaceutical Holdings to verify with the relevant parties and explain that Benchao Hui Pharmaceutical and Lu Zhong
The traditional Chinese medicine sector fell, while 600976.CN Group fell 9.61%.
[Caihua Social News] in early trading today, as of 10:15, the traditional Chinese medicine plate fell. Jianmin Group (600976.CN) fell 9.61% to 71.22 yuan, 002728.CN fell 8.37% to 16.21 yuan, Longshen Rongfa (300534.CN) fell 7.05% to 12.27 yuan, Xintian Pharmaceutical (002873.CN) fell 6.87% to 18.02 yuan, 300181.CN (300181.CN) fell 6.72% to 9.72 yuan, Jichuan Pharmaceutical (600566.CN) fell 6.26% to 25.9 yuan, Jilin Pharmaceutical
Analysis
Price Target
No Data
